Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people on levothyroxine are told the same thing after their labs come back: your TSH is normal, your thyroid is being treated, you are fine. And if you still feel exhausted, or foggy, or like your metabolism has slowed to a crawl, the implication is that something else must be causing it.

But there is a step between taking the medication and feeling better that almost nobody tests, and understanding that step explains why so many people stay symptomatic for years while their labs look perfectly normal.

Start with the full picture first. Your thyroid gland, when it is working, produces two hormones: T4 and T3. T3 is the active form, the one that actually enters your cells and drives energy production, metabolism, temperature regulation, and cognitive function. T4 is largely inactive on its own. It is more like a storage form, a precursor that your body needs to convert into T3 before it can be used.

Here is the part that matters: your thyroid only produces about 20% of the T3 circulating in your body. The other 80% comes from a conversion process that happens in your liver, your kidneys, and your gut, where specialized enzymes strip one iodine atom off T4 to produce usable T3.

Those enzymes are called deiodinases, which are essentially molecular scissors that modify thyroid hormones at the tissue level. There are three types, but the most relevant here are D1 and D2, which perform the conversion in peripheral tissues. They are not passive enzymes. They respond to the nutritional environment, the inflammatory environment, and your genetic makeup, and that responsiveness is exactly where the problem begins.

When your doctor prescribes levothyroxine, they are prescribing synthetic T4. The entire therapeutic model rests on the assumption that your conversion machinery is working well enough to take that T4 and produce sufficient T3. That assumption is checked with a TSH test, which measures a signaling hormone released by the pituitary gland in the brain.

The problem is that TSH reflects what the pituitary sees, not what your liver is doing, not what your gut is doing, not what is actually arriving at your cells as active hormone. A normal TSH tells you that the feedback loop at the brain level is balanced. It does not tell you whether the conversion that generates 80% of your active T3 is functioning adequately in the rest of your body.

This is not a theoretical gap. Research comparing levothyroxine-treated patients who had normal TSH against the general population found that treated patients had T3 to T4 ratios that were 15 to 20% lower, meaning they were running with systematically less active hormone despite looking normal on the standard test. And in those same studies, up to 40% of patients on levothyroxine with normal TSH still reported significant symptoms: fatigue, cognitive difficulty, weight issues, mood changes.

A large online survey of hypothyroid patients found that the majority were dissatisfied with their treatment outcomes even when they were considered medically well-controlled, and a common theme was persistent symptoms that their providers attributed to causes other than thyroid function.

So why does conversion fail? There are several reasons and they often overlap.

The deiodinase enzymes are selenoproteins, which means they require selenium to function. Without adequate selenium, the conversion machinery slows down. A study in pediatric patients with selenium deficiency found elevated free T4 alongside reduced T3, which is exactly what you would expect if the enzymes converting T4 to T3 were impaired. The body has T4 available but cannot process it efficiently.

Chronic inflammation is another driver. Inflammatory cytokines downregulate deiodinase activity, which is why people with autoimmune conditions, chronic infections, or metabolic dysfunction often have impaired conversion even when their thyroid gland itself is still functioning. In Hashimoto's thyroiditis, the autoimmune inflammation that destroys thyroid tissue also suppresses peripheral conversion, so the disease hits both the 20% of T3 the thyroid makes directly and the 80% the rest of the body is supposed to generate from T4.

Liver dysfunction matters here too, because the liver is one of the primary sites for T4 to T3 conversion and an impaired liver will reduce that output.

Then there is the genetic layer. Between 12 and 36% of people carry a variant in the DIO2 gene, which encodes the D2 deiodinase enzyme. This variant reduces the enzyme's efficiency, meaning these individuals have a structural, inherited limitation on their ability to convert T4 into T3. A study published in the Journal of Clinical Endocrinology and Metabolism found that patients with this DIO2 variant reported significantly worse psychological well-being on T4 only therapy, and showed measurable improvement when combination T4 plus T3 therapy was introduced. Their TSH was normal the entire time.

This is where the standard testing model breaks down at a mechanistic level. If 12 to 36% of the population has genetically reduced conversion capacity, and if conversion is the source of 80% of active T3, then testing only TSH in these patients is measuring the feedback signal from a process that is already compromised. The signal looks fine because the pituitary is getting what it needs. The body is not.

What you can do with this information starts with asking for a free T3 test alongside your TSH. Free T3 measures the unbound, bioavailable form of active hormone and is a direct window into whether conversion is actually occurring at a useful level. A normal TSH combined with a low or low-normal free T3 is the specific pattern that suggests a conversion problem rather than a production problem.

If that pattern is present, or if symptoms persist despite normal TSH, 200 micrograms of selenium per day is a reasonable starting point to support enzyme function, and this is worth reviewing with your provider given that selenium at higher doses has a narrow therapeutic window.

For patients with confirmed low free T3 and ongoing symptoms despite optimized levothyroxine dosing, combination therapy using both T4 and T3 is a clinically recognized option, and the DIO2 research specifically identifies the subgroup most likely to benefit from it.

Your medication is doing exactly what it was designed to do: deliver T4 into your bloodstream. But T4 is not the hormone your cells use. If the conversion system that produces 80% of your active hormone was never tested, and if any of the factors that impair it are present in your case, then treating a normal TSH as evidence that you are adequately treated is treating a map as if it were the territory.

The map can look right while the territory is still broken.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness